1-20 of 26
Guillermo Garcia-Manero, M.D.
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Experience with the Combination of a Hypomethylating Agent and Valproic Acid in Pediatric Acute Myelogenous Leukemia

Free
Michael Rytting, M.D., Patrick Zweidler-McKay, M.D., Ph.D., Yang Hui, Hagop Kantarjian, M.D., Guillermo Garcia-Manero, M.D.
Journal: Blood
Blood (2008) 112 (11): 4036.
https://doi.org/10.1182/blood.V112.11.4036.4036
Published: 2008
Journal Articles

Imatinib Frontline Therapy Is Safe and Effective in Patients with Chronic Myeloid Leukemia (CML) with Liver and/or Renal Dysfunction.

Free
Weigang Tong, M.D., Ph.D., Hagop Kantarjian, M.D., Susan O’Brien, M.D., Stefan Faderl, MD, Farhad Ravandi, MBBS, William G Wierda, M.D., Ph.D., Steven Kornblau, M.D., Gautam Borthakur, M.D., Guillermo Garcia-Manero, M.D., Elizabeth Burton, Mary Beth Rios, Jorge Cortes, M.D.
Journal: Blood
Blood (2008) 112 (11): 2126.
https://doi.org/10.1182/blood.V112.11.2126.2126
Published: 2008
Journal Articles

Antileukemia Activity of JNJ-26481585, a Potent Second-Generation Histone Deacetylase Inhibitor

Free
Weigang Tong, M.D., Ph.D., Yue Wei, Ph.D., William Stevenson, M.D., Ph.D., Shao-Qing Kuang, M.D., Ph.D., Janine Arts, Ph.D., Guillermo Garcia-Manero, M.D.
Journal: Blood
Blood (2008) 112 (11): 2631.
https://doi.org/10.1182/blood.V112.11.2631.2631
Published: 2008
Journal Articles

Phase II Study of Dasatinib (SPRYCEL™) in Philadelphia Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis.

Free
Srdan Verstovsek, MD, PhD, Tefferi Ayalew, M.D., Cortes Jorge, M.D., Susan O’Brien, M.D., Guillermo Garcia-Manero, M.D., Animesh Pardanani, M.D., Cem Akin, M.D., Stefan Faderl, M.D., Deborah Thomas, M.D., Hagop Kantarjian, M.D.
Journal: Blood
Blood (2007) 110 (11): 3551.
https://doi.org/10.1182/blood.V110.11.3551.3551
Published: 2007
Journal Articles

Intensively Timed Induction (ITI) Chemotherapy in Adults with Acute Myelogenous Leukemia (AML).

Free
Michael Rytting, MD, Srdan Verstovsek, M.D., Ph.D., Guillermo Garcia-Manero, M.D., Farhad Ravandi-Kashani, M.D., Sherry Pierce, R.N., Elihu Estey, M.D.
Journal: Blood
Blood (2007) 110 (11): 1851.
https://doi.org/10.1182/blood.V110.11.1851.1851
Published: 2007
Journal Articles

Phase II Study of Lenalidomide and Prednisone for Patients with Myelofibrosis.

Free
Alfonso Quintás-Cardama, MD, Ayalew Tefferi, M.D., Deborah Thomas, M.D., Jorge Cortes, M.D., Farhad Ravandi, M.D., Stefan Faderl, M.D., Guillermo Garcia-Manero, M.D., Gautam Borthakur, M.D., Neda Bell, M.D., Catriona Byrne, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D., Ph.D
Journal: Blood
Blood (2007) 110 (11): 3545.
https://doi.org/10.1182/blood.V110.11.3545.3545
Published: 2007
Journal Articles

Pegylated Interferon-alfa-2a (PEG-IFN-α-2A; PEGASYS™) for Essential Thrombocythemia (ET) and Polycythemia Vera (PV): An Update of an Ongoing Phase II Study.

Free
Alfonso Quintás-Cardama, MD, Hagop Kantarjian, M.D., Guillermo Garcia-Manero, M.D., Jorge Cortes, M.D., Marie Ann Richie, Gautam Borthakur, M.D., Srdan Verstovsek, M.D., Ph.D.
Journal: Blood
Blood (2007) 110 (11): 3542.
https://doi.org/10.1182/blood.V110.11.3542.3542
Published: 2007
Journal Articles

Phase II Study of CEP701, an Orally Available JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis.

Free
Srdan Verstovsek, MD, PhD, Ayalew Tefferi, M.D., Steven Kornblau, M.D., Deborah Thomas, M.D., Jorge Cortes, M.D., Farhad Ravandi-Kashani, M.D., Guillermo Garcia-Manero, M.D., Hagop Kantarjian, M.D.
Journal: Blood
Blood (2007) 110 (11): 3543.
https://doi.org/10.1182/blood.V110.11.3543.3543
Published: 2007
Journal Articles

PEG-Intron Therapy in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders (MPD): Final Result of a Phase II Study.

Free
Elias Jabbour, MD, Hagop Kantarjian, M.D., Charles A. Koller, M.D., Stefan Faderl, M.D., Alessandra Ferrajoli, M.D., Mary Ann Richie, R.N., Guillermo Garcia-Manero, M.D., Jorge Cortes, M.D., Zeev Estrov, M.D., Farhad Ravandi-Kashani, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.
Journal: Blood
Blood (2006) 108 (11): 3636.
https://doi.org/10.1182/blood.V108.11.3636.3636
Published: 2006
Journal Articles

Effect of Failure To Respond to Targeted Therapy on Response to Cytotoxic Therapy in Pts Age ≥ 60 with Newly-Diagnosed AML.

Free
Elihu H. Estey, MD, Guillermo Garcia-Manero, M.D., Francis Giles, M.D., Hagop M. Kantarjian, M.D.
Journal: Blood
Blood (2006) 108 (11): 1965.
https://doi.org/10.1182/blood.V108.11.1965.1965
Published: 2006
Journal Articles

Prognostic Significance of β-2 Microglobulin Levels in Acute Myeloid Leukemia: Analysis of 1293 Patients.

Free
Apostolia-Maria Tsimberidou, MD, PhD, Hagop M. Kantarjian, M.D., Michael J. Keating, M.D., Susan O’Brien, M.D., Sijin Wen, M.S., Jorge Cortes, M.D., Francis Giles, M.D., Charles Asa Koller, M.D., Guillermo Garcia-Manero, M.D., Sherry Pierce, B.S.N., Mark Brandt, Emil J. Freireich, M.D., Elihu H. Estey, M.D.
Journal: Blood
Blood (2006) 108 (11): 802.
https://doi.org/10.1182/blood.V108.11.802.802
Published: 2006
Journal Articles

Clinical Features and Prognosis of Patients with Myelodysplastic/Myeloproliferative Syndrome-Unclassified (MDS/MPD-U): Refractory Anemia with Ringed Sideroblasts with Thrombocytosis (RARS-T) Is a Favorable Prognostic Subgroup.

Free
Ehab Atallah, MD, Hagop Kantarjian, M.D., Jorge Cortes, M.D., Sherry Pierce, R.N., Elihu Estey, M.D., Guillermo Garcia-Manero, M.D., Deborah Thomas, M.D., Farhad Ravandi-Kashani, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.,; PhD.
Journal: Blood
Blood (2006) 108 (11): 2612.
https://doi.org/10.1182/blood.V108.11.2612.2612
Published: 2006
Journal Articles

Survival Benefit with Decitabine Compared to Historical Experience with Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome (MDS).

Free
Elias Jabbour, MD, Hagop M. Kantarjian, M.D., Jorge Cortes, M.D., William G. Wierda, M.D., Ph.D., Alessandra Ferrajoli, M.D., Stefan Faderl, M.D., Susan O’Brien, M.D., Farhad Ravandi-Kashani, M.D., Srdan Verstovsek, M.D., Ph.D., Guillermo Garcia-Manero, M.D., Jan Davisson, BS, ADN, Francis Giles, M.D., Jianqin Shan, Ph.D., Jean-Pierre Issa, M.D.
Journal: Blood
Blood (2006) 108 (11): 2652.
https://doi.org/10.1182/blood.V108.11.2652.2652
Published: 2006
Journal Articles

Characteristics and Outcomes of 38 Patients with Acute Myeloid Leukemia Evolving from Previous Well Characterized Myeloproliferative Disorder.

Free
Constantine S. Tam, MD, Francis Giles, M.D., Jorge Cortes, M.D., Guillermo Garcia-Manero, M.D., Elihu Estey, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D.;PhD
Journal: Blood
Blood (2006) 108 (11): 2705.
https://doi.org/10.1182/blood.V108.11.2705.2705
Published: 2006
Journal Articles

A Phase II Study of Azacitidine (Vidaza™) for Patients with Myelofibrosis (MF).

Free
Alfonso Quintas-Cardama, MD, Hagop Kantarjian, M.D., Guillermo Garcia-Manero, M.D., Deborah Thomas, M.D., STeven Kornblau, M.D., Elihu Estey, M.D., Marilyn Nemri, R.N., Jorge Cortes, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.;PhD
Journal: Blood
Blood (2006) 108 (11): 2706.
https://doi.org/10.1182/blood.V108.11.2706.2706
Published: 2006
Journal Articles

Survival Advantage for Patients (pts) with Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) Treated with Imatinib.

Free
Jorge Cortes, M.D., Moshe Talpaz, M.D., Susan O’Brien, M.D., Guillermo Garcia-Manero, M.D., Farhad Ravandi-Kashami, M.D., Francis Giles, M.D., Stefan Faderl, M.D., William Wierda, M.D., Jianqin Shan, Ph.D., Mary Beth Rios, R.N., Hagop Kantarjian, M.D.
Journal: Blood
Blood (2004) 104 (11): 1006.
https://doi.org/10.1182/blood.V104.11.1006.1006
Published: 2004
Journal Articles

Long-Term Incidence and Outcome of BCR-ABL Mutations in Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Mesylate - P-Loop Mutations Are Not Associated with Worse Outcome.

Free
Elias Jabbour, M.D., Hagop Kantarjian, M.D., Dan Jones, Ph.D., M.D., Susan O’Brien, M.D., Raja Luthra, Ph.D., Guillermo Garcia-Manero, M.D., Francis Giles, M.D., Mary Beth Rios, R.N., Srdan Verstovsek, M.D., Jorge Cortes, M.D.
Journal: Blood
Blood (2004) 104 (11): 1007.
https://doi.org/10.1182/blood.V104.11.1007.1007
Published: 2004
Journal Articles

A Phase I Study of Tipifarnib in Combination with Imatinib Mesylate (IM) for Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Who Failed IM Therapy.

Free
Jorge Cortes, M.D., Guillermo Garcia-Manero, M.D., Susan O’Brien, M.D., Ingrid Hernandez, R.N., Wayne Rackoff, M.D., Stefan Faderl, M.D., Deborah Thomas, M.D., Alessandra Ferrajoli, M.D., Moshe Talpaz, M.D., Hagop Kantarjian, M.D.
Journal: Blood
Blood (2004) 104 (11): 1011.
https://doi.org/10.1182/blood.V104.11.1011.1011
Published: 2004
Journal Articles

Is the Proposed World Health Organization (WHO) Classification for Chronic Myeloid Leukemia (CML) of Clinical Value in the Imatinib Era?.

Free
Jorge Cortes, M.D., Susan O’Brien, M.D., Guillermo Garcia-Manero, M.D., Stefan Faderl, M.D., Jenny Shan, Ph.D., Francis Giles, M.D., Srdan Verstovsek, M.D., Mary Beth Rios, R.N., Moshe Talpaz, M.D., Hagop Kantarjian, M.D.
Journal: Blood
Blood (2004) 104 (11): 1014.
https://doi.org/10.1182/blood.V104.11.1014.1014
Published: 2004
Journal Articles

Clinical Significance of Molecular Monitoring in Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Imatinib Therapy.

Free
Jorge Cortes, M.D., Moshe Talpaz, M.D., Susan O’Brien, M.D., Dan Jones, M.D., Ph.D., Raja Luthra, Ph.D., Guillermo Garcia-Manero, M.D., Francis Giles, M.D., Jenny Shan, Ph.D., Srdan Verstovsek, M.D., Ph.D., Mary Beth Rios, R.N., Hagop Kantarjian, M.D.
Journal: Blood
Blood (2004) 104 (11): 272.
https://doi.org/10.1182/blood.V104.11.272.272
Published: 2004